GeoVax Labs, Inc. advanced the GEO-MVA program within an evolving preparedness framework to maintain long-term orthopox preparedness.
Published
Signal category
Research & Knowledge
Quote
“GeoVax's GEO-MVA program is being advanced within this evolving preparedness framework.”
— GeoVax Labs, Inc. team
Company
GeoVax Labs, Inc.
Currently in Multiple Phase 2 Vaccine Trials
- Industry
- Biotechnology Research
- Location
- Smyrna, US
- Company size
- 26 employees
GeoVax Labs, Inc., (NASDAQ: GOVX) is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our Modified Vaccinia Ankara - Virus-Like Particle (MVA-VLP) vaccine platform. Our current development programs are focused on vaccines against COVID-19; Hemorrhagic Fever viruses such as Ebola (Zaire, Sudan), Lassa and Marburg; Malaria and Zika virus; and, Human Immunodeficiency Virus (HIV). We have also initiated programs to develop a broadly applicable immunotherapy against tumor associated antigen MUC1 that is expressed of many solid tumor types including breast, ovarian, gastric, liver, pancreas, renal and lymph nodes and immunotherapy to treat human papilloma virus (HPV)-induced cancers. For more information, visit www.geovax.com.